Strategii de prevenire a preeclampsiei. Farmacocinetica şi farmacodinamica heparinelor cu greutate moleculară mică în sarcină

Preeclampsia is a disease characteristic only to human preg­nan­cy, birth being its only healing method. The mor­bi­dity and mortality associated with this condition are con­si­derable, there­fore therapies aimed at preventing the development of preeclampsia, which could delay the onset of the disease or decrease its severity, are essential. Pregnant women with an increased risk of thromboembolic disease require anti­coa­gulant treatment throughout pregnancy. The effects and pharmacokinetics of the anticoagulant treatment used are mandatory to be known, given that in some cases the teratogenic effect may be present and in all cases the adap­tation of the treatment near and during labor must be indi­vidualized. The low-molecular-weight heparin (LMWH) response is more predictable than unfractionated heparin, and in the context of adverse effects and unlikely overdose, routine monitoring by biological tests is not required. For each patient undergoing anticoagulant treatment during pregnancy for the purpose of preventing thrombotic injury, there should be explained the signs and symptoms of throm­bosis, taking into account the fact that, even though the throm­bo­tic risk is very low under anticoagulant treatment, a degree of risk still persists in pregnancy. Preeclampsia risk as­ses­sment project aims to gather all the data regarding the per­so­nal and familial history, obsterical and clinical data that impact the risk of developing a hypertensive pathology in pregnancy.